Antisense Therapeutics (ASX:ANP) has announced that new data on ATL1102 in Duchenne muscular dystrophy (DMD) will be presented in a poster presentation at a leading conference in the US.
DMD is an X-linked disease that affects 1 in 3,600 to 6,000 live male births. It occurs as a result of mutations in the dystrophin gene that causes a substantial reduction in or absence of the dystrophin protein.
ATL1102, an antisense inhibitor of the CD49d receptor, recently reported promising Phase II trial results. ATL1102 has also successfully completed a Phase II efficacy and safety trial.
The Muscular Dystrophy Association (MDA) Clinical and Scientific Conference is being held from 13-16 March. The e-poster presentation is titled 'ATL1102 treatment in non-ambulant boys with DMD modulates plasma proteins with roles in TGF-beta mediated fibrosis, and cartilage and bone physiology'.
The presentation will be given by Dr George Tachas, Antisense Therapeutics director of drug discovery and patents.
The MDA conference is the largest of its kind in highlighting unprecedented research advancements and clinical achievements in neuromuscular diseases (NMD). The conference will explore all aspects of pre-clinical, translational, and clinical research and care across neuromuscular diseases to support the development of better care and treatments.
